Foghorn Therapeutics (FHTX) said Monday it has decided to discontinue the independent development of FHD-286 in combination with decitabine to treat patients with relapsed and/or refractory acute myeloid leukemia.
The company is evaluating collaborations and investigator sponsored trials for advancing FHD-286, it said, adding that it will now prioritize investment in proprietary pipeline and Lilly partnership programs.
Foghorn said it had $267.4 million in cash, cash equivalents and, marketable securities as of Sept. 30 to support its operations through 2027.
Foghorn's stock fell more than 20% in recent Monday premarket activity.
Price: 4.23, Change: -1.07, Percent Change: -20.19
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。